{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:54:31Z","timestamp":1788990871325,"version":"build-2803163510"},"reference-count":41,"publisher":"Baskent University","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.6002\/ect.2022.0315","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T02:46:29Z","timestamp":1675133189000},"page":"1076-1084","source":"Crossref","is-referenced-by-count":1,"title":["Transplant of Kidneys From Hepatitis C Virus-Positive Donors To Hepatitis C Virus-Negative Recipients: A Retrospective Study and Systematic Review"],"prefix":"10.6002","volume":"20","author":[{"given":"Halinuer","family":"Shadekejiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4021","reference":[{"key":"ref0","unstructured":"References"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-1730. doi:10.1056\/NEJM199912023412303","DOI":"10.1056\/NEJM199912023412303"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"2. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2011). 2018;8(3):91-165. doi:10.1016\/j.kisu.2018.06.001","DOI":"10.1016\/j.kisu.2018.06.001"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"3. Lentine KL, Smith JM, Hart A, et al. OPTN\/SRTR 2020 Annual Data Report: Kidney. Am J Transplant. 2022;22 Suppl 2:21-136. doi:10.1111\/ajt.16982","DOI":"10.1111\/ajt.16982"},{"key":"ref4","unstructured":"4. World Health Organization. Hepatitis C: key facts. Published June 24, 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"5. Xie Q, Xuan JW, Tang H, et al. Hepatitis C virus cure with direct acting antivirals: clinical, economic, societal and patient value for China. World J Hepatol. 2019;11(5):421-441. doi:10.4254\/wjh.v11.i5.421","DOI":"10.4254\/wjh.v11.i5.421"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"6. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325(7):454-460. doi:10.1056\/NEJM199108153250702","DOI":"10.1056\/NEJM199108153250702"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"7. Tesi RJ, Waller K, Morgan CJ, et al. Transmission of hepatitis C by kidney transplantation: the risks. Transplantation. 1994;57(6):826-831. doi:10.1097\/00007890-199403270-00010","DOI":"10.1097\/00007890-199403270-00010"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13(12):2974-2982. doi:10.1097\/01.asn.0000034944.90425.75","DOI":"10.1097\/01.ASN.0000034944.90425.75"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"9. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003;14(11):2908-2918. doi:10.1097\/01.asn.0000090743.43034.72","DOI":"10.1097\/01.ASN.0000090743.43034.72"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"10. Flohr TR, Bonatti H, Hranjec T, et al. Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease. J Surg Res. 2012;176(2):629-638. doi:10.1016\/j.jss.2011.10.028","DOI":"10.1016\/j.jss.2011.10.028"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"11. Singh N, Neidlinger N, Djamali A, et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant. 2012;26(5):684-693. doi:10.1111\/j.1399-0012.2011.01583.x","DOI":"10.1111\/j.1399-0012.2011.01583.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"12. Gupta G, Kang L, Yu JW, et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: analysis of United States national data. Clin Transplant. 2017;31(10). doi:10.1111\/ctr.13055","DOI":"10.1111\/ctr.13055"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"13. Rostaing L, Alric L, Kamar N. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transpl Int. 2016;29(12):1257-1265. doi:10.1111\/tri.12870","DOI":"10.1111\/tri.12870"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"14. Awan AA, Jadoul M, Martin P. Hepatitis C in chronic kidney disease: an overview of the KDIGO Guideline. Clin Gastroenterol Hepatol. 2020;18(10):2158-2167. doi:10.1016\/j.cgh.2019.07.050","DOI":"10.1016\/j.cgh.2019.07.050"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"15. Chute DF, Chung RT, Sise ME. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney Int. 2018;93(3):560-567. doi:10.1016\/j.kint.2017.10.024","DOI":"10.1016\/j.kint.2017.10.024"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"16. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394-2395. doi:10.1056\/NEJMc1705221","DOI":"10.1056\/NEJMc1705221"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"17. Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273-281. doi:10.7326\/M18-0749","DOI":"10.7326\/M18-0749"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"18. Yao L, Zhou H, Wang Y, et al. Hypothermic machine perfusion in DCD kidney transplantation: a single center experience. Urol Int. 2016;96(2):148-151. doi:10.1159\/000431025","DOI":"10.1159\/000431025"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"19. Hu XJ, Zheng J, Li Y, et al. Prediction of kidney transplant outcome based on different DGF definitions in Chinese deceased donation. BMC Nephrol. 2019;20(1):409. doi:10.1186\/s12882-019-1557-x","DOI":"10.1186\/s12882-019-1557-x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"20. Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533-540. doi:10.7326\/M17-2871","DOI":"10.7326\/M17-2871"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"21. Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience. Hepatology. 2020;72(1):32-41. doi:10.1002\/hep.31011","DOI":"10.1002\/hep.31011"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"22. Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transplant. 2019;19(11):3046-3057. doi:10.1111\/ajt.15530","DOI":"10.1111\/ajt.15530"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"23. Gupta G, Yakubu I, Bhati CS, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant. 2020;20(3):739-751. doi:10.1111\/ajt.15664","DOI":"10.1111\/ajt.15664"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"24. Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5(7):649-657. doi:10.1016\/S2468-1253(20)30081-9","DOI":"10.1016\/S2468-1253(20)30081-9"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"25. Graham JA, Torabi J, Ajaimy M, et al. Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access. Clin Transplant. 2020;34(4):e13833. doi:10.1111\/ctr.13833","DOI":"10.1111\/ctr.13833"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"26. Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687. doi:10.1681\/ASN.2020050686","DOI":"10.1681\/ASN.2020050686"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"27. Sise ME, Strohbehn IA, Chute DF, et al. Preemptive treatment with elbasvir and grazoprevir for hepatitis C-viremic donor to uninfected recipient kidney transplantation. Kidney Int Rep. 2020;5(4):459-467. doi:10.1016\/j.ekir.2020.01.001","DOI":"10.1016\/j.ekir.2020.01.001"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"28. Durand CM, Barnaba B, Yu S, et al. Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study. Ann Intern Med. 2021;174(1):137-138. doi:10.7326\/M20-1468","DOI":"10.7326\/M20-1468"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"29. Terrault NA, Burton J, Ghobrial M, et al. Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors. Hepatology. 2021;73(6):2110-2123. doi:10.1002\/hep.31551","DOI":"10.1002\/hep.31551"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"30. Torabi J, Rocca JP, Ajaimy M, et al. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis. 2021;23(1):e13449. doi:10.1111\/tid.13449","DOI":"10.1111\/tid.13449"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"31. Molnar MZ, Azhar A, Tsujita M, et al. Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes. Am J Kidney Dis. 2021;77(5):739-747 e731. doi:10.1053\/j.ajkd.2020.10.017","DOI":"10.1053\/j.ajkd.2020.10.017"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"32. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790-2802. doi:10.1111\/ajt.14381","DOI":"10.1111\/ajt.14381"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"33. European Association for the Study of the Liver. Clinical Practice Guidelines Panel C. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170-1218. doi:10.1016\/j.jhep.2020.08.018","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref34","unstructured":"34. University of Liverpool. HEP Drug Interactions. https:\/\/www.hep-druginteractions.org\/"},{"key":"ref35","unstructured":"35. National Health Commission of the People's Republic of China. National essential drug list; 2018. http:\/\/www.gov.cn\/fuwu\/2018-10\/30\/5335721\/files\/e7473e46d9b24aadad3eb25127ffd986.pdf"},{"key":"ref36","unstructured":"36. National Health Commission of the People's Republic of China. Negotiated drugs during the agreement period; 2020. http:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-12\/28\/5574062\/files\/ede5bafa6d9e4b29b49f21fa5d104d8a.pdf"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"37. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477-1492. doi:10.1093\/cid\/ciy585","DOI":"10.1093\/cid\/ciy585"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"38. Jafari A, Najivash P, Khatami MR, Dashti-Khavidaki S. Cytopenia occurrence in kidney transplant recipients within early post-transplant period. J Res Pharm Pract. 2017;6(1):31-39. doi:10.4103\/2279-042X.200983","DOI":"10.4103\/2279-042X.200983"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"39. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation. 2007;83(7):874-882. doi:10.1097\/01.tp.0000257923.69422.4d","DOI":"10.1097\/01.tp.0000257923.69422.4d"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"40. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc. 2008;40(3):752-754. doi:10.1016\/j.transproceed.2008.02.048","DOI":"10.1016\/j.transproceed.2008.02.048"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:24:47Z","timestamp":1675135487000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2022\/20\/12\/0\/1076\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2022.0315","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}